Ann: MXC to Commence Australian Dementia Trial with Notre Dame, page-2

The hints were there! I am trying to work the timeline out for this product. I am putting aside any fast-tracking that may be able to be done.
The Phase 2 Trial will start in early 2019 and go for at least 16 weeks. So it is reasonable to conclude that the results will be known sometime at half year.
The phase 3 trial is next. The estimated time for these phase 3 trials would be at least 1 year and could be as much as 4. I would suggest it may only be a year.
So the product could come on line sometime late 2020.
Now there is potential for it to be fast tracked but better to put conservative numbers than "the quickest possible time".
Potential market? 425 000 in Australia alone. Using cannepil as the example (100=1 mill in revenue) It is pretty clear that even a small percentage is going to produce huge revenue. 1% of 425 000 is 4250. If the revenue is similar to cannepil then you are looking at about 42 million in revenue. Still a couple of years away but that would be impressive ….